Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the …
$5.81-23.55%
报价 2026-11-06
市值
$140.7M
EV
$173M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -39.4%
$2.65$9.59
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
market cap below $300M floor
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| XGNExagen Inc. | $140.7M | -23.6% | +7.7% | 58.6% | – | – | – | |
| NEONeoGenomics, Inc. | $2.19B | +2.1% | +10.3% | 42.9% | – | 54.0x | – | |
| ACRSAclaris Therapeutics, Inc. | $574.1M | +8.0% | -35.2% | 95.6% | – | – | – | |
| SGHTSight Sciences, Inc. | $555.3M | +3.3% | +11.3% | 88% | – | – | – | |
| TKNOAlpha Teknova, Inc. | $481.9M | -0.9% | +9.5% | 33.9% | – | – | – | |
| SMTISanara MedTech Inc. | $289.9M | -0.2% | +14.4% | 91.3% | – | 37.4x | 71.2x | |
| LFCRLifecore Biomedical, Inc. | $241.1M | -0.6% | +62.7% | 29.7% | – | – | – | |
| VNDAVanda Pharmaceuticals Inc. | $231M | +6.4% | +20.3% | 93.2% | – | – | – | |
| BIOABioAge Labs, Inc. | $201M | -3.6% | -16.9% | 99.4% | – | – | – | |
| 同行中位数 | – | – | +10.8% | 89.6% | – | 45.7x | 71.2x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。